Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Dr. Reddy’s Laboratories (RDY - Snapshot Report) recently announced the launch of its generic version of GlaxoSmithKline’s (GSK - Analyst Report) Amoxil (amoxicillin) tablets, capsules, and oral suspension in the US following the receipt of Food and Drug Administration (FDA) approval for its Abbreviated New Drug Application (ANDA).

Dr. Reddy’s launched its generic version of Amoxil tablets (500 mg and 875 mg), capsules (250 mg and 500 mg) and oral suspension (125 mg/5 ml, 200 mg/5 ml, 250 mg/5 ml, and 400 mg/5 ml) in the US on September 17, 2012.

Amoxil is marketed for the treatment of bacterial infection of the ear, nose, throat, genitourinary tract, skin and skin structure, and lower respiratory tract.

According to IMS Health, US branded and generic sales of Amoxil tablets (875 mg), capsules and oral suspension were approximately $22.2 million, $67.2 million and $89.5 million, respectively, for the twelve months ended June 30, 2012.

We note Dr. Reddy’s had quite a few generic launches this year. On September 11, 2012, it launched its generic version of AstraZeneca’s (AZN - Analyst Report) hypertension drug Toprol XL (metoprolol succinate extended release) - tablets (25 mg, 50 mg, 100 mg and 200 mg) in the US.

Dr. Reddy’s also launched a generic version of Merck & Co.’s (MRK - Analyst Report) blockbuster asthma and allergy drug Singulair and Pfizer Inc.’s (PFE - Analyst Report) blockbuster cholesterol drug, Lipitor. Other recent launches include Dr. Reddy’s generic version of Roche Holdings Ltd.’s (RHHBY - Analyst Report) Boniva, Glaxo’s Requip and Novartis AG’s (NVS - Snapshot Report) over-the-counter (OTC) drug, Prevacid.

Our Recommendation

Currently, we have a Neutral recommendation on Dr. Reddy’s. The stock carries a Zacks #3 Rank (short-term Hold rating).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%